News

Neximmune Receives IND Clearance for Phase 1/2 Trial in Relapsed / Refractory Multiple Myeloma

December 19, 2019

NexImmune, a valued MIF partner, received Investigational New Drug (IND) clearance for the company's second cellular therapy, developed to treat relapsed/refractory multiple myeloma patients.

Read more...

Myeloma Investment Fund F.A.Q.

November 20, 2019

Tidal President and CEO Ulrik Nielsen talks with us about the partnership with the MMRF and how it enhances the development of more precise treatments for multiple myeloma.

Read more...

In Quest for Cures, Medical Nonprofits Seek to Wield Their Own Venture Funding Power

May 31, 2019

Advocates for disease research diving into fundraising in bid to wield more influence inside the startup ecosystem.

Read more...

Multiple Myeloma Research Foundation (MMRF) Venture Philanthropy Fund Invests in NexImmune to Advance Novel Immunotherapy Candidate Into Clinical Trials

April 29, 2019

Partnership yields the first investment from newly launched MMRF Myeloma Investment Fund.

Read more...

Multiple Myeloma Research Foundation (MMRF) Launches Novel Investment Fund to Drive Development of New Myeloma Treatments

April 16, 2019

Fund seeks to attract promising companies to the field, accelerating advances in multiple myeloma research and creating a self-sustaining investment model.

Read more...